drugset

drugset / Trial / NCT06886360

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

NCT06886360 ↗

Phase 3 Not yet recruiting 120 enrolled Dr. Falk Pharma GmbH

NaSingle-groupOpen-labelTreatment

Summary

Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis

Timeline

Start: 2025-03
Primary completion: 2027-09
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	norUrsodeoxycholic Acid	Unknown	1500 mg	Oral

Indications